Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pravastatin sodium -

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 10.825mg equivalent to atorvastatin 10 mg - film coated tablet - 10 mg - active: atorvastatin calcium trihydrate 10.825mg equivalent to atorvastatin 10 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 21.65mg equivalent to atorvastatin 20 mg - film coated tablet - 20 mg - active: atorvastatin calcium trihydrate 21.65mg equivalent to atorvastatin 20 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 43.3mg equivalent to atorvastatin 40 mg - film coated tablet - 40 mg - active: atorvastatin calcium trihydrate 43.3mg equivalent to atorvastatin 40 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - atorvastatin calcium trihydrate 86.6mg equivalent to atorvastatin 80 mg - film coated tablet - 80 mg - active: atorvastatin calcium trihydrate 86.6mg equivalent to atorvastatin 80 mg excipient: butylated hydroxyanisole colloidal silicon dioxide croscarmellose sodium sepifilm lp 010 magnesium stearate mannitol microcrystalline cellulose purified water sodium carbonate sodium laurilsulfate - indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin tablet is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pravastatin sodium, quantity: 20 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; colloidal anhydrous silica; dibasic sodium phosphate; croscarmellose sodium; povidone; lactose monohydrate; iron oxide red; magnesium stearate - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. patients with unstable angina pectoris (see clinical trials). as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).